INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in REGENXBIO Inc. of Class Action Lawsuit and Upcoming Deadlines – RGNX

Core Viewpoint - A class action lawsuit has been filed against REGENXBIO Inc. concerning allegations of securities fraud and unlawful business practices [2]. Group 1: Lawsuit Details - The lawsuit involves claims that Regenxbio and certain officers and/or directors engaged in securities fraud or other unlawful business practices [2]. - Investors have until April 14, 2026, to request to be appointed as Lead Plaintiff if they purchased Regenxbio securities during the Class Period [2]. Group 2: Recent Developments - On January 28, 2026, Regenxbio announced that the U.S. FDA placed a clinical hold on its investigational gene therapy RGX-111 for MPS I due to a case of neoplasm in a participant [4]. - The FDA also placed a clinical hold on RGX-121 for MPS II, citing similarities in products and shared risks between the studies [4]. - Following this announcement, Regenxbio's stock price fell by $2.40 per share, or 17.9%, closing at $11.01 per share on January 28, 2026 [4].